Gain Therapeutics’ (GANX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

GANX has been the subject of several other reports. Chardan Capital reiterated a buy rating and set a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Oppenheimer reiterated an outperform rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, August 14th.

Gain Therapeutics Price Performance

Shares of GANX opened at $2.07 on Wednesday. The company has a market cap of $52.85 million, a price-to-earnings ratio of -1.59 and a beta of 0.42. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average of $1.41 and a two-hundred day moving average of $1.96.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.11). As a group, analysts predict that Gain Therapeutics will post -1.05 earnings per share for the current fiscal year.

Insider Activity at Gain Therapeutics

In other Gain Therapeutics news, Chairman Khalid Islam bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the chairman now directly owns 50,000 shares of the company’s stock, valued at approximately $50,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Warberg Asset Management LLC purchased a new position in Gain Therapeutics in the second quarter valued at $66,000. Renaissance Technologies LLC increased its holdings in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics in the second quarter valued at $422,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.